box). Outlier values have not been visualised. Patients who underwent renal replacement therapy were excluded from the “Best Recovered” group. Figure 2 Time from initiation of 5-ASA agents to the development of nephrotoxicity and recovery of renal function to baseline level This graph displays the time in days from initiation of 5-ASA agents to the development of nephrotoxicity by the recovery status. The horizontal line illustrates the median for each cohort. Figure 3 A: Genome wide Manhattan plot (including HLA imputation) Blue line (P=1x10-5), Red line (P=5x10-8) B: QQ plot (including HLA-imputation) Figure 4 A: Genome wide Manhattan plot (including HLA imputation) excluding cases that did not have a renal biopsy demonstrating interstitial nephritis (n=55) for all SNPs with a MAF >0.05. Blue line (P=1x10-5), Red line (P=5x10-8) B: QQ plot (including HLA imputation) excluding cases that did not have a renal biopsy demonstrating interstitial nephritis (n=55) Supplementary Information IBD Pharmacogenetics Study Group
box). Outlier values have not been visualised. Patients who underwent renal replacement therapy were excluded from the “Best Recovered” group. Figure 2 Time from initiation of 5-ASA agents to the development of nephrotoxicity and recovery of renal function to baseline level This graph displays the time in days from initiation of 5-ASA agents to the development of nephrotoxicity by the recovery status. The horizontal line illustrates the median for each cohort. Figure 3 A: Genome wide Manhattan plot (including HLA imputation) Blue line (P=1x10-5), Red line (P=5x10-8) B: QQ plot (including HLA-imputation) Figure 4 A: Genome wide Manhattan plot (including HLA imputation) excluding cases that did not have a renal biopsy demonstrating interstitial nephritis (n=55) for all SNPs with a MAF >0.05. Blue line (P=1x10-5), Red line (P=5x10-8) B: QQ plot (including HLA imputation) excluding cases that did not have a renal biopsy demonstrating interstitial nephritis (n=55) Supplementary Information IBD Pharmacogenetics Study Group
5ASA_Nephrotoxocity_version_5.docx